Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    MoneyHero

    MCap

    USD60m

    Last close

    USD2.35

    ▲ 0.55 (30.56%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

InMed Pharmaceuticals (US: INM)

Last close As at 26/04/2024

0.37

▲ −0.02 (−5.13%)

Market capitalisation

USD6m

Edison Investment Research is terminating coverage on InMed Pharmaceuticals. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

View More

Healthcare | Update

InMed Pharmaceuticals — THCV launch expands rare cannabinoids portfolio

Healthcare | Update

InMed Pharmaceuticals — Health and wellness product launches

Healthcare | Outlook

InMed Pharmaceuticals — Notable launches of high-value rare cannabinoids

Healthcare | Update

InMed Pharmaceuticals — Generating commercial sales of CBC and CBT
Visit Website

Sector

Healthcare

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 2.6 (49.4) (82.2)
Relative (8.3) (53.6) (81.7)
52 week high/low US$2.4/US$0.4

Financials

Edison Investment Research is terminating coverage on InMed Pharmaceuticals. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Y/E Jun Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (c) P/E (x) P/CF (x)
2020A 0.0 (9.0) (9.0) (172.80) N/A N/A
2021A 0.0 (9.8) (10.3) (153.02) N/A N/A
2022E 1.8 (14.6) (14.8) (97.62) N/A N/A
2023E 10.2 (13.2) (13.8) (63.67) N/A N/A

edison tv

Healthcare

Webinar: InMed Pharmaceuticals

Update

Healthcare

InMed Pharmaceuticals — NM-755 Phase II about to begin

Update

Healthcare

InMed Pharmaceuticals — Acquiring BayMedica

edison tv

Healthcare

InMed Pharmaceuticals and BayMedica – executive interview

edison tv

Healthcare

Webinar: InMed Pharmaceuticals

Update

Healthcare

InMed Pharmaceuticals — Phase II enrolment to begin in second half

edison tv

Healthcare

InMed Pharmaceuticals – Edison Open House interview

Update

Healthcare

InMed Pharmaceuticals — INM-755 Phase I complete, on to Phase II

edison tv

Healthcare

Executive interview – InMed’s cannabinol (CBN) formulation for glaucoma

edison tv

Healthcare

Executive interview – InMed: Leading the way in the therapeutic development of cannabinol (CBN)

Update

Healthcare

InMed Pharmaceuticals — INM-755 trial full enrollment expected this quarter

edison tv

Healthcare

Executive interview – InMed: A leader in the development of cannabinol (CBN) therapeutics

Update

Healthcare

InMed Pharmaceuticals — Developing cannabinol (CBN)

Update

Healthcare

InMed Pharmaceuticals — CTA filed on schedule

Update

Healthcare

InMed Pharmaceuticals — INM-755 getting closer to the clinic

edison tv

Healthcare

Executive interview – InMed Pharmaceuticals

Update

Healthcare

InMed Pharmaceuticals — Fiscal Q319 results

Update

Healthcare

InMed Pharmaceuticals — Entering the clinic by the end of the year

Update

Healthcare

InMed Pharmaceuticals — Biosynthesis and INM-750 Progress on Track

Update

Healthcare

InMed Pharmaceuticals — Progressing their programs

Initiation

Healthcare

InMed Pharmaceuticals — Innovating cannabinoids